Zylö announces the creation and spinout of Atticus Pharma Inc.
April 17, 2024 08:00 ET
|
Zylö Therapeutics
Atticus to focus on biopharma applications of the innovative ‘Powered by Z-pod®’ topical-delivery platform GREENVILLE, SC, April 17, 2024 (GLOBE NEWSWIRE) -- Zylö recently effected a spinout of...
Zylö’s ‘Powered by Z-pods®’ technology incorporated into BosleyMD’s new product line
February 06, 2024 15:15 ET
|
Zylö Therapeutics
The breakthrough product, Revive+ Densifying Foam for hair growth, is now for sale at CVS GREENVILLE, SC, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zylö’s Z-pod® topical delivery platform is being used...
Zylö accepted into NYU’s exclusive Endless Frontier Labs mentorship program
October 03, 2023 08:30 ET
|
Zylö Therapeutics
GREENVILLE, SC, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics has been selected to join the Endless Frontier Labs (EFL) 2023-2024 cohort alongside 77 other startups. Over 1,400 companies...
Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology
September 27, 2023 08:30 ET
|
Zylö Therapeutics
Z-pods significantly improved outcomes in mouse model of cutaneous lupus GREENVILLE, SC, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The Z-pod® topical delivery platform was used in various in vivo...
Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program
May 31, 2023 13:00 ET
|
Zylö Therapeutics
Funds to be used to demonstrate efficacy in a new mouse model of cutaneous lupus GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery...
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
September 16, 2022 08:30 ET
|
Zylö Therapeutics
Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...
Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)
August 19, 2022 09:00 ET
|
Zylö Therapeutics
Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...
Zylö Therapeutics Closes $5.225 Million Series B Financing
June 03, 2022 09:00 ET
|
Zylö Therapeutics
GREENVILLE, SC, June 03, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series...
Zylö’s Erectile Dysfunction Product Concept Wins Best Abstract Award
November 10, 2021 09:00 ET
|
Zylö Therapeutics
The product concept uses patent-pending Z-pods™ to sustainably—for over an hour—release nitric oxide GREENVILLE, SC, Nov. 10, 2021 (GLOBE NEWSWIRE) -- A novel nitric-oxide-releasing product concept...
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
July 20, 2021 09:00 ET
|
Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...